-+ 0.00%
-+ 0.00%
-+ 0.00%

Kiniksa Q3 2026 net income more than doubles to $47.35 million

PUBT·10/27/2026 11:36:02
Kiniksa Q3 2026 net income more than doubles to $47.35 million
  • Kiniksa Pharmaceuticals’ third-quarter 2026 net income more than doubled year over year to $47.35 million.
  • Revenue climbed 58% year over year to $286 million, with management citing gains in patient and physician adoption of ARCALYST.
  • The pivotal Phase 3 trial of KPL-387 continues enrolling and dosing patients, with data expected in the second half of 2027.
  • Kiniksa raised the upper end of its 2026 ARCALYST revenue outlook to $1.05 billion and expects annual cash-flow positivity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270730PRIMZONEFULLFEED1001280048) on October 27, 2026, and is solely responsible for the information contained therein.